Notably, PRMT1 knockdown enhanced the antitumor efficacy of cetuximab in both KRAS mutant and WT CRC cells, suggesting that targeting PRMT1 may sensitize CRC cells to cetuximab regardless of KRAS mutation status [26]. Here, KRAS is linked to colorectal carcinoma.